Zentalis Pharmaceuticals (ZNTL)

• Market cap: $191M
• 1 day: 2.79%
• 5 days: -14.74%
• 1 month: 110.71%
• 3 months: 79.88%
• 6 months: 112.23%
• Year to date: 115.33%
• 1 year: 31.11%
• 5 years: -93.13%
• 10 years: -87.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 166